Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Japanese subjects with advanced malignancies
NCT03235570Phase 1Completed
- Sponsor
- Incyte
- Start
- Aug 2017
- Primary completion
- Mar 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pemigatinib in solid tumor, sponsored by Incyte. Primary endpoint: Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events. Started Aug 2017; status: completed.
02
Drugs
pemigatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03235570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235570.